HeartBeam (NASDAQ: BEAT) announced a commercial partnership with ClearCardio, a preventive cardiology practice, establishing ClearCardio as HeartBeam's first commercial customer while planning an investment in the company. The agreement, structured as a Letter of Intent with subscription-based commercial terms, will integrate HeartBeam's synthesized 12-lead ECG technology into ClearCardio's cardiac prevention programs for arrhythmia assessment. This staged rollout enables patients to capture clinical-grade ECG readings from home using HeartBeam's patented cable-free 3D ECG system, which received FDA clearance for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025.
The partnership represents a significant milestone in HeartBeam's broader growth strategy, including expansion into concierge care and preventive cardiology networks. HeartBeam's technology platform creates the first cable-free device capable of collecting ECG signals in three non-coplanar directions and synthesizing them into a 12-lead ECG, designed for portable use wherever patients are located. This approach allows physicians to identify cardiac health trends and acute conditions outside medical facilities, potentially redefining cardiac health management. The company holds over 20 issued patents related to technology enablement, with detailed information about cleared indications available at https://www.heartbeam.com/indications.
ClearCardio serves thousands of patients through heart health screening and personalized prevention programs, making this partnership strategically aligned with both organizations' objectives. The collaboration supports HeartBeam's continued development of its 12-lead ECG patch monitor and advancement of AI-driven cardiac care initiatives. This commercial deployment demonstrates real-world application of technology that previously existed primarily as a cleared medical device, moving from regulatory approval to clinical implementation in preventive care settings.
The announcement comes as HeartBeam positions itself within the growing remote patient monitoring market, where technologies enabling clinical-grade assessments outside traditional healthcare facilities are increasingly important. By integrating with ClearCardio's established preventive cardiology practice, HeartBeam gains access to a patient population that can benefit from regular cardiac monitoring while providing data that could inform broader cardiac care initiatives. The investment component from ClearCardio further solidifies the strategic relationship between the two organizations, suggesting confidence in both the technology and its commercial potential within preventive cardiology networks.
